. CCN2-interacting proteins and receptors of CCN2. CCN2 protein interacts with a variety of cell-surface signal-transducing receptors and extracellular ligands, including various integrins, heparan sulfate proteoglycans (HSPG), and LRPs. Receptors and extracellular proteins that interact with 3 of the 4 conserved CCN2 domains are shown.
One of the most prominent functions of CCN2 is its role in cell adhesion. When immobilized on solid surfaces in cell cultures, CCN2 proteins can support the adhesion of most adherentcell types through integrins and HSPGs and induce adhesive signaling. Adhesion of CCN2 to human skin fibroblasts occurs through 6 1-HSPGs and rapidly induces the formation of 6 1-containing focal adhesion complexes, activation of focal adhesion kinase (FAK), paxillin, and Rac, as well as reorganization of the actin cytoskeleton and formation of filopodia and lamellipodia (C. C. Chen, et al., 2001 ). CCN2 can serve as an adaptor for other extracellular matrix proteins to promote cell adhesion, as exemplified by the binding of CCN2 to fibronectin and perlecan (Y. Chen, et al., 2004; Nishida, et al., 2003) . In addition to supporting cell adhesion, one of the ubiquitous activities of CCN proteins is the regulation of cell migration.
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Role of Connective Tissue Growth Factor (CTGF/CCN2) in Oral Squamous Cell Carcinoma-Induced Bone Destruction 177 CCN2 proteins stimulate the migration of many mesenchymal cell types (Babic, et al., 1999; Grzeszkiewicz, et al., 2001; Lin, et al., 2003; Shimo T, et al., 1998; Shimo T, et al., 1999) .
CCN2 was originally discovered in, and purified from, the conditioned medium of cultured vein endothelial cells (Bradham, et al., 1991) . In 1998, Shimo et al. reported that knockdown of ccn2 expression results in the suppression of the proliferation and migration of normal vascular endothelial cells (Shimo T, et al., 1998) . Subsequently, CCN2 was shown to induce angiogenesis in corneal implants (Babic, et al., 1999) and chick chorioallatonic membranes (Shimo T, et al., 1999) . CCN2 also induces chemotaxis (inducing directional cell migration) and chemokinesis (random cell movement) in endothelial cells (Babic, et al., 1999; Babic, et al., 1998; Lin, et al., 2003; Shimo T, et al., 1999) . Through direct binding to integrin v 3, CCN2 can recapitulate angiogenic events in vitro by promoting endothelial cell adhesion, migration, proliferation, and tubule formation (Babic, et al., 1999; Leu, et al., 2002; Lin, et al., 2003; Shimo T, et al., 1999) .
CCN2 knockout mice die just after birth due to respiratory failure (Ivkovic S, et al., 2003) . This failure is attributed to hypoplasia of the thoracic skeleton and deformity of the oral cavity (palatal cleft and shortened mandible). CCN2 knockout mice also show skeletal dysmorphisms as a result of impaired chondrocyte proliferation and reduced extracellular matrix with altered composition within the hypertrophic chondrocytic zone in the growth plate. Histologically, angiogenesis and formation of tartrate-resistant acid phosphatase (TRAP)-positive osteoclast-like cells, as well as critical protease expression in the growth plate, are impaired and accompanied by defective replacement of cartilage by bone during endochondral ossification Nishida T, et al., 2000; Shimo T, et al., 2005 ). These results demonstrate that CCN2 is important for cell proliferation and matrix remodeling during chondrogenesis, and is a key regulator coupling extracellular matrix remodeling to angiogenesis at the growth plate. The biological activities of CCN2 also include the development of Meckel's cartilage (Shimo T, et al., 2004) and tooth germs .
Next we will summarize research indicating the essential roles of CCN2 and related molecules in the bone destruction caused by cancer.
Cancers and CCN2
CCN2 proteins carry out their biological activity through binding and cell surface integrins (Lau LF & Lam SC, 1999) , and elevated CCN2 expression has been observed in breast cancers (Xie D, et al., 2001) , pancreatic cancers (Wenger C, et al., 1999) , melanomas (Kubo M, et al., 1998) , chondrosarcomas (Shakunaga T, et al., 2000) , and squamous cell carcinomas (Shimo T, et al., 2008) . Although CCN2 shows multiple roles in various cancer types, in breast tumor cells CCN2 over-expression has been linked to an increase in tumor size, lymph node metastasis (Chen PS, et al., 2007; Xie D, et al., 2001) , and drug resistance through up-regulation of the survival pathway (Wang MY, et al., 2009) . CCN2 is also regarded as a central mediator of tumor angiogenic factor in certain malignancies (Kondo S, et al., 2002; Shimo T, et al., 2001a; Shimo T, et al., 2001b) . It should be noted that CCN2 is one of the contributors to bone metastasis, as it converts low-metastatic breast cancer cells to high-metastatic ones in collaboration with other factors (Kang Y, et al., 2003; Minn AJ, et al., 2005) . Neutralizing antibodies against CCN2 significantly inhibit local tumor growth, www.intechopen.com angiogenesis, and osteolysis caused by metastatic human breast cancer cells (Shimo T, et al., 2006) . CCN2 and PTHrP are strongly expressed in cancer cells that have invaded the bone matrix, and CCN2 expression is regulated by PTHrP through PKA, PKC, and ERK1/2 MAPK pathways (Shimo T, et al., 2006) . Furthermore, the CCN2 gene is significantly overexpressed in overt metastatic tumor cells as compared with its expression in disseminated tumor cells in the bone marrow of breast cancer patients by CT-guided bone metastasis biopsy and bone marrow biopsy (Cawthorn, et al., 2009) . Fig. 2A illustrates a representative radiographic pattern of invasive bone destruction observed in a patient with oral squamous cell carcinoma in the mandibular region. In such cases, as shown in Fig. 2B , tumor cells fill the bone marrow space and destroy both the trabecular and cortical bone of the mandible. Tumor. The data were modified from Shimo et al. (Shimo, et al., 2008 ) (B and D).
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Role of Connective Tissue Growth Factor (CTGF/CCN2) in Oral Squamous Cell Carcinoma-Induced Bone Destruction 179 CCN2 is abundantly produced by the tumor cells that have invaded the bone matrix (Fig.  2C) ; and, interestingly, CCN2 is also present in the osteoclasts at the destroyed bone/tumor cell interface (Fig. 2D, arrowheads) . Of note, up-regulation of CCN2 in oral squamous cell carcinoma of the mandible is associated with increased bone destruction (Shimo T, et al., 2008) . These data suggest that CCN2 can be considered both a diagnostic marker and target for treatment of oral osteolytic mandibular squamous cell carcinoma.
Relation between CCN2 and tumor associated factors and signaling

Insulin-like growth factor (IGF) and CCN2
The insulin-like growth factor (IGF) is the most abundant factor stored in the bone matrix (Hauschka, et al., 1986) . The IGF system comprises hormone-like growth factors (IGF-I and II), cell-surface receptors (IGF-IR, IGF-IIR and insulin receptor), circulating binding proteins (IGFBPs), and IGFBP proteases. Activation of IGF-I/IGFR signaling plays an important role in cancer cells, leading to an increase in cell proliferation, invasion/migration, to a decrease in apoptosis, and to resistance to antineoplastic agents, suggesting that IGF/IGFR plays an important role in mammary tumorigenesis (Brady, et al., 2007; Kimura, et al., 2010; Saxena, et al., 2008) . A larger family of secreted cysteine-rich proteins, made so by inclusion of the Twisted gastrulation (TSG), IGFBP, and CCN families, is termed TIC (Flint, et al., 2008; Pell, et al., 2005) . Interestingly, members of the CCN protein family bind IGF with low affinity (Hwa, et al., 1999) . However, there are only a few published reports on the association between IGF system and CCN proteins.
Parathyroid hormone-related protein (PTHrP) and CCN2
Parathyroid hormone-related protein (PTHrP) has important developmental roles in the embryonic skeleton and other tissues. Detection or increased plasma concentrations of PTHrP have been found in 80% of hypercalcemia patients with solid tumor (Burtis WJ, et al., 1990) . When it is produced in excess by cancer cells, it can cause hypercalcemia; and its local production by breast cancer cells has been implicated in the pathogenesis of bone metastasis in that disease. Localized production of PTHrP by cancer cells in such lesions was shown to promote the survival and proliferation of cancer cells and osteolysis in a mouse model (Guise TA, et al., 1996) . PTHrP induces both the production of RANKL and down-regulation of OPG production by osteoblasts, thereby stimulating osteoclastogenesis (Horwood NJ, et al., 1998; Lee SK & Lorenzo JA, 1999) . Oral squamous cell carcinoma cells provide a suitable microenvironment for osteoclast formation by producing PTHrP (Kayamori, et al., 2010) . Knock-down of PTHrP in oral squamous cell carcinoma cell caused decreased osteoclast formation in vitro, and suppressed tumor bone invasion in vivo (Y. Takayama, et al., 2010) . Sections of resected mandibles from patients with invasive oral squamous cell carcinoma showed strong expression of PTHrP in tumor cells and great number of osteoclasts at bone invasion sites (Y. Takayama, et al., 2010) . Type I PTH/PTHrP receptor (PTH1R) expression is specifically observed in cancer cells producing PTHrP and CCN2 that have invaded the bone marrow, and PTHrP strongly up-regulates CCN2 in MDA-MB-231 cells in vitro (Shimo T, et al., 2006) . CCN2 is also critically involved in osteolytic metastasis and is induced by PKA-and PKC-dependent activation of ERK 1/2 signaling by PTHrP (Shimo T, et al., 2006) .
Transforming growth factor- (TGF-) and CCN2
TGF- is by far the second abundant cytokine in bone, and must be considered as a central player in bone turnover (Bonewald LF & Mundy GR, 1990) and potentially able to couple bone resorption with bone formation (Karsdal MA, et al., 2001; Takeshita S, et al., 2000) . Restricted to the bone environment, target cells of TGF- include cancer cells as well as osteoblasts, osteoclasts, their precursors in the bone marrow, and stromal cells (Bonewald LF & Mundy GR, 1990; Karsdal MA, et al., 2001) . TGF- is a pleiotropic cytokine that plays a central role in maintaining epithelial homeostasis. In early carcinogenesis, TGF- acts as a tumor suppressor by inhibiting cell proliferation (Massague J, et al., 2000; Sun L, 2004) . However, several studies showed that primary tumor cells in the late stage can reprogram their response to TGF- by dysregulation or mutational inactivation of various components of the TGF- signaling pathway and through cross-interaction with other oncogenic pathways (Nagaraj & Datta, 2010) . TGF- transduces its signal through 2 highly conserved single transmembrane serine/threonine kinase receptors, termed type I (T RI) and type II (T RII). T RII activates T RI upon formation of a ligand-receptor complex by hyperphosphorylating serine/threonine residues in the GS region of T RI. Activated T RI in turn phosphorylates Smad2 and Smad3, which interact with Smad4. Their complex is translocated to the nucleus, where it regulates the transcription of target genes. This signalling cascade initiates broad cellular and noncellular processes including proliferation and differentiation, migration and motility, and deposition of extracellular matrix, as well as induces the production of cytokines contributing to tumorigenesis, metastasis, and angiogenesis (Ge, et al., 2006; Petersen, et al., 2010) . Due to its central role in TGFsignalling, T RI is emerging as a novel target for the blockade of the tumor-promoting and metastasis activities of the TGF-pathway (Shinto, et al., 2010) . Consequently, the TGF- signal becomes a bone metastasis-promoting one (Kang Y, et al., 2005; Kominsky SL, et al., 2007; Yin JJ, et al., 1999) . T RI-positive signals are closely associated with destructive invasion of the mandible by oral squamous cell carcinoma cells, and a T RI-inhibitor greatly reduces oral squamous cell carcinoma cell-induced bone destruction and osteoclast formation both in vivo and in vitro (Goda, et al., 2010) . TGF- is one of the most potent inducers of CCN2, promoting CCN2 expression in bone metastatic cancer cells (Kang Y, et al., 2003) ; and the induction occurs through a complex network of transcriptional interactions requiring Smads, protein kinase C, and ras/MEK/ERK, as well as an Ets-1/transcription enhancer factor-binding element in the CCN2 promoter Leask A, et al., 2002; Van Beek JP, et al., 2006) . TGFreleased from the bone causes a further increase in the expression of the TGF--responsive osteoclast-inducing genes, CCN2, RANKL, and TNF-in oral squamous cell carcinoma cells, thus establishing a composite positive-feedback cycle of metastasis (Kang Y, et al., 2003; Shimo T, et al., 2006) .
RANKL and CCN2
The RANK and its ligand RANKL signaling pathway play pivotal role in osteoclastmediated bone resorption in both normal bone remodeling and in pathological conditions, including bone metastasis (Boyle WJ, et al., 2003; Lacey DL, et al., 1998; Simonet WS, et al., 1997) . RANK is a transmembrane signaling receptor of the tumor necrosis factor (TNF) receptor superfamily that is expressed on the surface of osteoclast precursors (Hsu H, et al., 1999; Nakagawa N, et al., 1998) . Its cognate ligand, RANKL, is expressed almost exclusively within the bone marrow stromal cell compartment and is up-regulated by most hormones and factors that stimulate bone resorption (Boyle WJ, et al., 2003; Roodman GD & Dougall WC, 2008) . The interaction between RANK and RANKL is necessary for osteoclast formation, function, and survival (Kong YY, et al., 1999; Lacey DL, et al., 1998) . RANKL (50 ng/ml) stimulates osteoclastogenesis in mouse total bone marrow cells in the presence of 100 ng/ml CCN2 (Shimo T, et al., 2008) . Stromal/osteoblastic cells are essential for in vitro osteoclastogenesis through cell-to-cell interactions (Kondo Y, et al., 2001 ). The expression of CCN2 is up-regulated in the cells of mouse macrophage cell line RAW264.7 after treatment with RANKL, and CCN2 synergistically promotes RANKL-induced osteoclast differentiation by interacting with dendritic cell-specific transmembrane protein (DC-STAMP) on the surface of osteoclast-like cells (Nishida, et al., 2011) . Therefore, it has been hypothesized that CCN2 may facilitate cell-to-cell signaling by interacting with multiple molecules on the surface of these cells through integrin (Gao R & Brigstock DR, 2004; Hoshijima, et al., 2006) , proteoglycans , and growth factors (Inoki I, et al., 2002) .
Endothelin-1 (ET-1) and CCN2
Endothelin-1 (ET-1) is also a key mediator of osteoblastic bone metastasis, which is characteristic of breast and prostate cancers (Nelson JB, et al., 1995; Yin JJ, et al., 2003) . Functional inhibition of ET-1 activity by blocking its receptor, ETA, significantly decreases bone metastasis in an experimental bone metastasis model involving the osteoblastic breast cancer cell line ZR-75-1 Yin JJ, et al., 2003) .
CCN2 is one of the secreted factors downstream of ET-1, as determined from microarray analysis of osteoblasts (Clines GA, et al., 2007) . ET-1 activates the CCN2 promoter and induces CCN2 expression in cardiomyocyte cells (Recchia AG, et al., 2009 ). Furthermore, ET-1 induces CCN2 in an additive fashion with TGF-through an element distinct from the TGF- response element (Horstmeyer A, et al., 2005; Shi-Wen X, et al., 2008; Xu SW, et al., 2004) .
Integrins and CCN2
Integrin have been shown to be critical in controlling how tumor cells interact with their microenvironment. The integrin v 3 is a receptor for osteopontin, fibronectin, and vitronectin, which are extracellular matrix proteins important in the bone matrix (Schneider, et al., 2011) ; and v 3 has been identified as one of the CCN2 receptors (C. C. Chen, et al., 2001) . Bone metastatic cancer cells have a higher expression of v 3 than their primary tumor (Liapis, et al., 1996) , promoting adherence to the bone matrix (S. Takayama, et al., 2005) . The over-expression of v 3 in the tumor cells not only leads to increased tumor cell adhesion, migration, and invasion to bone, but also increases osteoclast recruitment at the tumor and bone interface (Pecheur, et al., 2002; Sloan, et al., 2006) . Whereas, 5 1 , another signaling receptor mediating CCN2 action, plays a necessary role in the binding of prostate cancer tumor cells to the bone stroma (Van der Velde-Zimmermann, et al., 1997) , and in skeletal metastasis of breast cancer cells (Korah, et al., 2004) .
Bone-invading destructive tumor cells enhance osteoclast function and recruitment. v 3 is the predominant integrin found on osteoclasts, and is responsible for mediating osteoclastbone recognition (Crippes, et al., 1996; Liapis, et al., 1996; Ross, et al., 1993; Zambonin Zallone, et al., 1989) and subsequent attachment to the bone matrix (Chellaiah, 2006; Ross, et al., 1993) . This signaling creates the characteristic resorptive ruffled membrane, as well as regulates OC spreading and the overall organization of the cytoskeleton (Faccio, et al., 2003; McHugh, et al., 2000) .
Wnt signaling and CCN2
The Wnt signaling pathways are initiated by a combination of ligands and receptors formed from among 19 secreted Wnt ligands, 10 Frizzled receptors, with the involvement of the coreceptor LRP5/6, which is lipoprotein receptor-related protein 5/6. These ligand-receptor interactions then lead to the activation of multiple intermediate Wnt effectors includingcatenin, c-Jun-NH 2 -kinase, and calcium-channel regulators. The accumulation of -catenin in the cytoplasm and its translocation to the nucleus represent the hallmark of the activated canonical Wnt pathway. In the nucleus, -catenin forms a complex with lymphocyte enhancer factor/T-cell factor family of transcription factors to activate many oncogenes, such as c-Myc, cyclin D1, metalloproteinases, c-Met, etc (Fuerer, et al., 2008; Rubin, et al., 2010) .
The Wnt/ -catenin signaling pathway is an important target for eliminating cancer stem cell in head and neck squamous cell carcinomas (Song, et al., 2010) . The importance of paracrine Wnt signaling in bone metastasis was first revealed in multiple myeloma (Tian, et al., 2003) , a plasma cell leukemia that causes severe osteolytic bone disease. The results revealed that one of the tumor-secreted factors responsible for the enhanced osteolysis is the Wntinhibitor DKK-1 (Tian, et al., 2003) . In prostate cancer cells, high DKK-1 expression is correlated with osteolytic disease, consistent with the findings in multiple myeloma; whereas low DKK-1 expression is associated with osteosclerotic bone metastases (Schwaninger, et al., 2007) . Functional inhibition of Wnt singling by DKK-1 over-expression in prostate cancer cells favors the formation of osteolytic bone metastases (Hall, et al., 2005) .
Si et al. (Si, et al., 2006 ) observed a significant up-regulation of CCN2 gene expression in mesenchymal stem cells that had been stimulated by Wnt3A. Osteoblasts and stromal cells of transgenic mice that over-express CCN2 display reduced Wnt--catenin signaling (Smerdel-Ramoya, et al., 2008) . Over-expression of CCN2 in esophageal squamous carcinoma cells results in the accumulation and nuclear translocation of -catenin leading to activation of TCF-LEF signaling and up-regulation of c-myc and cyclin D1 (Deng, et al., 2007) .
Role of CCN2 in tumor/bone microenvironment
In the bone marrow microenvironment affected by a tumor, substantial bone marrow angiogenesis is present compared with that in healthy persons (Chavez-Macgregor, et al., 2005) . CCN2, the best-characterized factor in its family is known to promote the proliferation www.intechopen.com
Role of Connective Tissue Growth Factor (CTGF/CCN2) in Oral Squamous Cell Carcinoma-Induced Bone Destruction 183 Fig. 3 . Role of CCN2 in tumor-induced bone destruction. The cross-talk between tumor cells and osteoclasts is not direct, but involves molecular and cellular intermediates; e.g., tumor cells secrete parathyroid-hormone-related peptide (PTHrP), which is the primary stimulator of osteoblast production of RANKL (Roodman GD, 2004) . PTHrP induces CCN2 in tumor cells (Shimo T, et al., 2008) ; on the other hand, PTHrP both up-regulates the production of RANKL and down-regulates OPG production by osteoblasts, thereby stimulating osteoclastogenesis (Horwood NJ, et al., 1998) . Other factors produced and secreted by tumor cells (TNF-, TGF-, macrophage colony-stimulating factor (M-CSF), IL-6, and prostaglandin E2) also increase the expression of RANKL. The increased expression of RANKL in the tumor environment leads to increased formation, activation, and survival of osteoclasts, which cells cooperate with these tumor-induced growth factors (CCN2, TNF-, TGF-, and M-CSF), resulting in osteolytic lesions. Osteolysis then leads to the release of growth factors derived from bone, including transforming growth factor- (TGF-), insulinlike growth factors (IGFs), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and bone morphogenetic proteins (BMPs). These factors increase the production of PTHrP and CCN2 or promote tumor growth directly and cause neovascularization. Bone destruction increases local extracellular calcium (Ca 2+ ) concentrations, which have also been shown to promote tumor growth and the production of PTHrP (Roodman GD, 2004) . Thus, tumor cell proliferation and production of tumor-associated factors through the signaling of positive-feedback pathways is promoted, thus giving rise to a "vicious cycle." The Scheme was modified from (Shimo T, et al., 2011) .
 
www.intechopen.com and differentiation of not only vascular endothelial cells but also fibroblasts and osteoblasts (C. C. Chen, et al., 2001; Nishida T, et al., 2000; Shimo T, et al., 1998; Shimo T, et al., 1999) . CCN2 protein is able to interact with multiple molecules in the bone microenvironment, which interaction results in the modulation of the extracellular molecular network therein. The angiogenic effect of CCN2 is the result of the interaction of it with adhesion molecules (Gao R & Brigstock DR, 2004) , cell-surface signal transducing receptors (Wahab, et al., 2005) , proteoglycans , and growth factors (Inoki I, et al., 2002) .
Bone-derived growth factors, such as TGF-, FGFs, PDGFs, BMPs, and IGF-1, are activated and released into the bone microenvironment. Elevated TGF- does not appear to affect tumor growth, but rather leads to the production of PTHrP (Guise TA, 2000) and CCN2 (Kang Y, et al., 2003; Shimo T, et al., 2006) in cancer cells, thus establishing a continuously destructive cycle termed the "vicious cycle" through up-regulation of RANKL and accelerated bone resorption. Of note, CCN2 is known to interact with these growth factors (Abreu JG, et al., 2002; Inoki I, et al., 2002) or regulate the gene expression of some of them (Shimo T, et al., 2001b) . As a result, CCN2 may be anticipated to modulate the effects of these growth factors on the osteoblast-induced RANKL and OPG expression, osteoclast formation or osteoclast activation in regions affected by bone metastasis (Fig. 3) . The other critical function of CCN2 is exerted by its interaction with extracellular matrix molecules and cell-adhesion molecules. By interacting with integrins, functions and other proteins and proteoglycans, CCN2 may promote adhesion and migration of osteoclast precursor cells and stimulate osteoclast formation and activation (Shimo T, et al., 2008) . CCN2 not only promotes the expression of DC-STAMP, which plays an important role in cell-cell fusion, but also interacts with this molecule to promote osteoclast differentiation (Nishida, et al., 2011) . CCN2 may thus be an integrator/modulator of extracellular information and appears to allow the establishment and progression of tumor angiogenesis and bone destruction within the skeleton (Kubota S & Takigawa M, 2007a; Sasaki A, et al., 1998; Sasaki A, et al., 2003) .
Conclusions
The initiation of osteoclastogenesis and angiogenesis is the most fundamental step leading to tumor-induced bone destruction. From a clinical point of view, osteoclast formation and angiogenesis would be the major targets of therapeutic drugs for tumor bone metastasis. The major modulator of these processes, referring to osteoclast formation and angiogenesis has been shown to be the CCN2 molecule, which is thus now regarded as a potential target of anti-osteoclastogenic and angiogenic therapy (Aikawa, et al., 2006; Shimo T, et al., 2006) . These findings strongly suggest that CCN2 may be a suitable molecular target for therapy of advanced oral squamous cell carcinoma.
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